Below are the most recent publications written about "Trypanosoma cruzi" by people in Profiles.
-
Guedes-da-Silva FH, Batista DDGJ, Da Silva CF, Pavão BP, Batista MM, Moreira OC, Souza LRQ, Britto C, Rachakonda G, Villalta F, Lepesheva GI, Soeiro MNC. Successful Aspects of the Coadministration of Sterol 14a-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi. ACS Infect Dis. 2019 03 08; 5(3):365-371.
-
Ortega-Rodriguez U, Portillo S, Ashmus RA, Duran JA, Schocker NS, Iniguez E, Montoya AL, Zepeda BG, Olivas JJ, Karimi NH, Alonso-Padilla J, Izquierdo L, Pinazo MJ, de Noya BA, Noya O, Maldonado RA, Torrico F, Gascon J, Michael K, Almeida IC. Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of a-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas Disease. Methods Mol Biol. 2019; 1955:287-308.
-
Friggeri L, Hargrove TY, Rachakonda G, Blobaum AL, Fisher P, de Oliveira GM, da Silva CF, Soeiro MNC, Nes WD, Lindsley CW, Villalta F, Guengerich FP, Lepesheva GI. Sterol 14a-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae. J Med Chem. 2018 12 13; 61(23):10910-10921.
-
Suman S, Rachakonda G, Mandape SN, Sakhare SS, Villalta F, Pratap S, Lima MF, Nde PN. Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase. PLoS Negl Trop Dis. 2018 09; 12(9):e0006792.
-
Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018 04; 18(4):419-430.
-
Serrano M, Gonzalez V, Ray S, Chavez MD, Narayan M. Identification of Structure-Stabilizing Interactions in Enzymes: A Novel Mechanism to Impact Enzyme Activity. Cell Biochem Biophys. 2018 Jun; 76(1-2):59-71.
-
Brito CR, McKay CS, Azevedo MA, Santos LC, Venuto AP, Nunes DF, D'Ávila DA, Rodrigues da Cunha GM, Almeida IC, Gazzinelli RT, Galvão LM, Chiari E, Sanhueza CA, Finn MG, Marques AF. Virus-like Particle Display of the a-Gal Epitope for the Diagnostic Assessment of Chagas Disease. ACS Infect Dis. 2016 12 09; 2(12):917-922.
-
Ogindo CO, Khraiwesh MH, George M, Brandy Y, Brandy N, Gugssa A, Ashraf M, Abbas M, Southerland WM, Lee CM, Bakare O, Fang Y. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorg Med Chem. 2016 08 15; 24(16):3849-55.
-
De Pablos LM, Díaz Lozano IM, Jercic MI, Quinzada M, Giménez MJ, Calabuig E, Espino AM, Schijman AG, Zulantay I, Apt W, Osuna A. The C-terminal region of Trypanosoma cruzi MASPs is antigenic and secreted via exovesicles. Sci Rep. 2016 06 08; 6:27293.
-
Herrera LJ, Brand S, Santos A, Nohara LL, Harrison J, Norcross NR, Thompson S, Smith V, Lema C, Varela-Ramirez A, Gilbert IH, Almeida IC, Maldonado RA. Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Negl Trop Dis. 2016 Apr; 10(4):e0004540.